ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
Genmab A S (PK)

Genmab A S (PK) (GNMSF)

198.3125
0.00
( 0.00% )
업데이트: 22:18:35
고급 차트

개인 투자자를 위한 전문가급 도구.

주요 통계 및 세부정보

가격
198.3125
매수가
189.80
매도가
203.85
거래량
-
0.00 일간 변동폭 0.00
170.00 52주 범위 305.09
market_cap
전일 종가
198.3125
개장가
-
최근 거래 시간
마지막 거래 시간
-
재정 규모
-
VWAP
-
평균 볼륨(3m)
3,856
발행 주식
65,691,573
배당수익률
-
주가수익률
1.46
주당순이익(EPS)
119.41
매출
21.53B
순이익
7.84B

Genmab A S (PK) 정보

Genmab is an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Genmab is an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.

섹터
Biological Pds,ex Diagnstics
산업
Biogenetic (human)
웹사이트
본부
Copenhagen, Dnk
설립됨
2000
Genmab A S (PK) is listed in the Biological Pds,ex Diagnstics sector of the OTC 시장 with ticker GNMSF. The last closing price for Genmab A S (PK) was US$198.31. Over the last year, Genmab A S (PK) shares have traded in a share price range of US$ 170.00 to US$ 305.09.

Genmab A S (PK) currently has 65,691,573 shares in issue. The market capitalisation of Genmab A S (PK) is US$13.03 billion. Genmab A S (PK) has a price to earnings ratio (PE ratio) of 1.46.

GNMSF 최신 뉴스

기간변동변동 %시가고가저가평균 일일 거래량VWAP
16.81253.55744125326191.5204.9999190.5230196.90933808CS
42.46251.25733980087195.85204.99991704933184.89024593CS
125.65752.93659650671192.655242.73751703856190.41523088CS
26-24.6875-11.0706278027223242.73751705294207.20744638CS
52-81.4475-29.1133471547279.76305.091703823221.34075294CS
156-169.6875-46.1107336957368470.51701877259.78543084CS
260-27.8875-12.3286914235226.2500.921701685286.56789937CS

GNMSF - Frequently Asked Questions (FAQ)

What is the current Genmab A S (PK) share price?
The current share price of Genmab A S (PK) is US$ 198.3125
How many Genmab A S (PK) shares are in issue?
Genmab A S (PK) has 65,691,573 shares in issue
What is the market cap of Genmab A S (PK)?
The market capitalisation of Genmab A S (PK) is USD 13.03B
What is the 1 year trading range for Genmab A S (PK) share price?
Genmab A S (PK) has traded in the range of US$ 170.00 to US$ 305.09 during the past year
What is the PE ratio of Genmab A S (PK)?
The price to earnings ratio of Genmab A S (PK) is 1.46
What is the cash to sales ratio of Genmab A S (PK)?
The cash to sales ratio of Genmab A S (PK) is 0.53
What is the reporting currency for Genmab A S (PK)?
Genmab A S (PK) reports financial results in DKK
What is the latest annual turnover for Genmab A S (PK)?
The latest annual turnover of Genmab A S (PK) is DKK 21.53B
What is the latest annual profit for Genmab A S (PK)?
The latest annual profit of Genmab A S (PK) is DKK 7.84B
What is the registered address of Genmab A S (PK)?
The registered address for Genmab A S (PK) is KALVEBOD BRYGGE 43, COPENHAGEN, 1260
What is the Genmab A S (PK) website address?
The website address for Genmab A S (PK) is www.genmab.com
Which industry sector does Genmab A S (PK) operate in?
Genmab A S (PK) operates in the BIOGENETIC (HUMAN) sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
AACAFAAC Technologies Holdings Inc (PK)
US$ 3.90
(0.00%)
0
AABVFAberdeen International Inc (PK)
US$ 0.023278
(0.00%)
0
AABKFAareal Bank AG (CE)
US$ 0.00
(0.00%)
0
AABBAsia Broadband Inc (PK)
US$ 0.028
(0.00%)
0
AAAIFAlternative Investment Trust (PK)
US$ 0.55
(0.00%)
0
AACAFAAC Technologies Holdings Inc (PK)
US$ 3.90
(0.00%)
0
AABVFAberdeen International Inc (PK)
US$ 0.023278
(0.00%)
0
AABKFAareal Bank AG (CE)
US$ 0.00
(0.00%)
0
AABBAsia Broadband Inc (PK)
US$ 0.028
(0.00%)
0
AAAIFAlternative Investment Trust (PK)
US$ 0.55
(0.00%)
0
IPCKFPT Indonesia Kendaraan Terminal TBK (GM)
US$ 0.00
(0.00%)
974.9k
TBNRLTamboran Resources Corporation (PK)
US$ 0.115
(0.00%)
892.16k
DNAXDNA Brands Inc (PK)
US$ 0.0002
(0.00%)
500k
HRSHFHaier Smart Home Company Ltd (PK)
US$ 2.65
(0.00%)
452.58k
ATPMFAntipa Minerals Ltd (PK)
US$ 0.00
(0.00%)
314.45k

GNMSF 금융

금융

GNMSF Discussion

게시물 보기
XenaLives XenaLives 5 년 전

Products in development
Genmab is developing a pipeline of antibody therapeutics with eighteen products in clinical development, including two marketed products, and approximately 20 in-house and partnered pre-clinical programs. Our pipeline currently includes naked antibodies, Antibody Drug Conjugates (ADCs), bispecific antibodies created from our DuoBody® technology platform, and antibodies created with our HexaBody® technology.


http://www.genmab.com/product-pipeline/products-in-development
👍️0
XenaLives XenaLives 5 년 전

Product pipeline
Genmab has two partnered products on the market, DARZALEX® (daratumumab) and Arzerra® (ofatumumab), and is developing a clinical pipeline of antibody therapeutics for the treatment of cancer.


http://www.genmab.com/product-pipeline

👍️0
XenaLives XenaLives 5 년 전

About Genmab A/S
Genmab A/S operates as a biotechnology company. The Company specializes in development of antibody therapeutics for the treatment of cancer. Genmab serves customers worldwide.


ADDRESS
Kalvebod Brygge 43 Copenhagen V, 1560 Denmark
PHONE
45-7020-2728
WEBSITE
www.genmab.com






https://www.bloomberg.com/quote/GMXAY:US
👍️0
XenaLives XenaLives 5 년 전
GMXAY largest holding in Blackrock fund:

iShares Genomics Immunology and Healthcare ETF


https://www.blackrock.com/us/individual/products/308878/
👍️0
PennyStock Alert PennyStock Alert 6 년 전
Genmab Announces Phase II Study of Daratumumab in Non-Hodgkin's Lymphomas

[GlobeNewswire] - Company Announcement

read full: http://finance.yahoo.com/news/genmab-announces-phase-ii-study-063632870.html
👍️0
TenKay TenKay 7 년 전
GMXAY Forward Split 5 for 1 effective May 1, 2018

http://otce.finra.org/DailyList
👍️0
trendmkr trendmkr 9 년 전
Here are Two Biotech Stocks to Watch in January - article mentions Genmab

http://marketexclusive.com/here-are-two-biotech-stocks-to-watch-in-january/1228/
👍️0
stocktrademan stocktrademan 10 년 전
$GMXAY DD Notes ~ http://www.ddnotesmaker.com/GMXAY

bullish

$GMXAY recent news/filings

## source: finance.yahoo.com

Thu, 04 Dec 2014 06:36:32 GMT ~ Genmab Announces Phase II Study of Daratumumab in Non-Hodgkin's Lymphomas

[GlobeNewswire] - Company Announcement

read full: http://finance.yahoo.com/news/genmab-announces-phase-ii-study-063632870.html
*********************************************************

Mon, 24 Nov 2014 13:53:34 GMT ~ Genmab Announces Phase II Study of Daratumumab in Smoldering Multiple Myeloma

[GlobeNewswire] - Company Announcement

read full: http://finance.yahoo.com/news/genmab-announces-phase-ii-study-135334071.html
*********************************************************

Mon, 10 Nov 2014 08:17:15 GMT ~ Genmab Announces New Phase III Combination Study of Daratumumab in Frontline Multiple Myeloma

[GlobeNewswire] - Company Announcement

read full: http://finance.yahoo.com/news/genmab-announces-phase-iii-combination-081715458.html
*********************************************************

Thu, 06 Nov 2014 14:40:06 GMT ~ Genmab Announces Daratumumab and Ofatumumab Data to Be Presented at American Society of Hematology Annual Meeting (ASH)

[GlobeNewswire] - Media Release

read full: http://finance.yahoo.com/news/genmab-announces-daratumumab-ofatumumab-data-144006800.html
*********************************************************

Thu, 06 Nov 2014 14:10:48 GMT ~ Genmab Announces Additional Data from Phase III Study of Ofatumumab as Maintenance Therapy for Relapsed CLL

[GlobeNewswire] - COPENHAGEN, Denmark -- Genmab A/S (OMX: GEN) announced today additional data from the interim analysis of the ofatumumab (Arzerra(tm)) Phase III study, PROLONG (OMB112517). The study evaluated ofatumumab ...

read full: http://finance.yahoo.com/news/genmab-announces-additional-data-phase-141048186.html
*********************************************************


$GMXAY charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$GMXAY company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/GMXAY/company-info
Ticker: $GMXAY
OTC Market Place: OTC Pink Current
CIK code: 0001434265
Company name: Genmab A/S
Company website: http://www.genmab.com
Incorporated In: Denmark

Business Description: Genmab is an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.


$GMXAY share structure

## source: otcmarkets.com

Market Value: $2,578,167,309 a/o Dec 03, 2014
Shares Outstanding: 51,052,818 a/o Jul 30, 2013
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$GMXAY extra dd links

Company name: Genmab A/S
Company website: http://www.genmab.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=GMXAY+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=GMXAY+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=GMXAY+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/GMXAY/news - http://finance.yahoo.com/q/h?s=GMXAY+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/GMXAY/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/GMXAY/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=GMXAY+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/GMXAY
DTCC (dtcc.com): http://search2.dtcc.com/?q=Genmab+A%2FS&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Genmab+A%2FS
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Genmab+A%2FS&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.genmab.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.genmab.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.genmab.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/GMXAY
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001434265&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/GMXAY/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/GMXAY/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=GMXAY&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=GMXAY
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/GMXAY/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=GMXAY+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=GMXAY+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=GMXAY
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=GMXAY
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=GMXAY+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/GMXAY/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=GMXAY+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/GMXAY.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=GMXAY
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/GMXAY/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/GMXAY
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/GMXAY
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/GMXAY:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=GMXAY
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=GMXAY



$GMXAY DD Notes ~ http://www.ddnotesmaker.com/GMXAY
👍️0
akademikeren akademikeren 11 년 전
Genmab has taken a beating along with a lot of american Biotech. It is poised for a lot of news starting the 19th of april with a PDUFA date on their submission on 1st line CLL drug Arzerra. For those of you unfamiliar with this Company I will be posting news regularly and tell you something about the history.
👍️0